In New Zealand, sensorineural Hearing Loss is managed by ents. Sensorineural hearing loss accounts for roughly 90% of permanent adult hearing loss and arises from damage to cochlear hair cells, the cochlear nerve, or central auditory pathways. The World Health Organization estimates over 466 million people worldwide live with disabling hearing loss, projected to rise to 700 million by 2050.
Sensorineural hearing loss (SNHL, ICD-10: H90.3-H90.5) refers to hearing impairment caused by injury at any point from cochlear hair cells through the cochlear nerve to the central auditory cortex. The cochlea contains roughly 15,000 hair cells — 12,000 outer hair cells that amplify sound and 3,500 inner hair cells that transduce mechanical vibration into neural impulses. Hair cells do not regenerate in mammals, so their loss is permanent. SNHL is contrasted with conductive hearing loss (impaired sound transmission through outer or middle ear) and mixed hearing loss (both components).
The key symptoms of Sensorineural Hearing Loss are: Gradual decline in clarity of speech understanding, particularly consonants and high-pitched voices, often noticed by family members before the patient., Difficulty following conversation in restaurants, group meetings, or background noise despite preserved volume — the hallmark complaint of high-frequency presbycusis., Constant or intermittent ringing, buzzing, hissing, or roaring in one or both ears (tinnitus) accompanying 70-80% of sensorineural hearing loss cases., Sudden one-sided hearing loss developing within minutes to 72 hours, often noticed on waking, sometimes with aural fullness and dizziness — the hallmark of sudden SNHL., Increased volume of television, radio, or phone calls, sometimes leading to family conflict before the patient acknowledges a problem., Sounds described as muffled, distorted, or 'underwater' rather than just quiet — distinguishes SNHL from conductive loss., Difficulty localizing sound and judging the direction of approaching vehicles, particularly with asymmetric or unilateral hearing loss..
Workup begins with a detailed history — onset, laterality, fluctuation, noise exposure, ototoxic drugs, family history, head trauma, and associated tinnitus, vertigo, or aural fullness. Otoscopy excludes cerumen impaction, otitis media, or perforation. Tuning-fork tests at 512 Hz (Rinne, Weber) differentiate conductive from sensorineural patterns at the bedside; in pure SNHL the Rinne remains positive (air conduction louder than bone) and the Weber lateralizes to the better ear. Pure-tone audiometry from 250 Hz to 8 kHz with air and bone conduction is the diagnostic standard and quantifies severity, configuration, and side. Speech audiometry adds the speech reception threshold and word recognition score (WRS). For unilateral SNHL, asymmetric loss above 15 dB at two contiguous frequencies, or WRS asymmetry above 15%, an MRI of the internal acoustic meatus with gadolinium is mandatory to exclude vestibular schwannoma. In sudden SNHL the workup must not delay treatment: start oral or intratympanic steroids while arranging audiogram and MRI. Otoacoustic emissions and auditory brainstem response identify cochlear versus retrocochlear sites of lesion and screen newborns. Tympanometry rules out middle-ear disease as a cause of asymmetric thresholds. Genetic testing (GJB2 sequencing, expanded panels) is recommended in congenital and bilateral early-onset cases, and congenital CMV PCR on newborn dried blood spot or saliva should be obtained within 21 days of birth in any infant failing screening.
Outlook depends on cause, age at onset, and access to intervention. Idiopathic sudden SNHL recovers fully or partially in 50-65% of patients treated with steroids within 14 days; profound presentations recover less often (15-30%). Age-related and noise-induced hearing loss is progressive but consistent hearing-aid use slows the rate of social isolation, depression, and dementia. Cochlear implants restore open-set speech understanding in 60-80% of adult recipients within 12 months; children implanted under age 1 with appropriate rehabilitation achieve normal language milestones in 60-80%. Untreated bilateral severe-to-profound SNHL in adults is associated with a 3-5× higher risk of dementia (Lancet Commission 2020), 2-3× higher fall risk, and significant employment, social, and psychological consequences. Roughly 15% of profound congenital deafness is associated with progressive syndromic disease (Usher, Pendred, Alport) requiring multidisciplinary surveillance.
Otolaryngology (ENT) and audiology evaluate cause, exclude reversible pathology (cerumen, effusion), and stage severity. ENT is mandatory for sudden, asymmetric, or progressive loss because retrocochlear pathology must be excluded with MRI. Cochlear implant candidacy assessment, congenital hearing loss workup with CMV and genetic testing, and management of vestibular schwannoma all require subspecialty otology.
Find specialists →Sudden SNHL: most spontaneous and steroid-induced recovery occurs within 14 days; final hearing typically settled by 3 months. Hearing aid acclimatization: 4-12 weeks for adaptation, with full benefit at 3-6 months. Cochlear implant activation 3-4 weeks post-surgery, with rapid initial improvement and continued gains over 6-12 months. Pediatric cochlear implant language development tracks chronological age when implanted under 12 months and starts within 3 months of activation.
Regular aerobic activity (150 minutes per week of moderate intensity) is associated with lower rates of presbycusis through better cochlear blood flow. Wear hearing protection during loud exercise environments (spinning classes, gyms with amplified music). Avoid intense Valsalva maneuvers in patients with perilymph fistula or enlarged vestibular aqueduct because they risk acute hearing decline.
Choose an otologist or neuro-otologist with cochlear-implant volume above 30 cases per year and access to a dedicated audiology team. For sudden SNHL, prioritize a clinic able to start oral steroids and arrange intratympanic injection within 7 days. For pediatric loss, a multidisciplinary cochlear-implant program with speech and language therapy yields the best language outcomes. Many centers now include AAO-HNS quality measures (time to MRI, time to cochlear implant in eligible adults) in their public reporting.
Medically reviewed by AIHealz Medical Editorial Board · May 13, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in New Zealand.
Apply as specialist →Specialists who treat Sensorineural Hearing Loss. Get expert guidance and personalized care.